These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Bleeding symptoms in carriers of hemophilia A and B. Mauser Bunschoten EP; van Houwelingen JC; Sjamsoedin Visser EJ; van Dijken PJ; Kok AJ; Sixma JJ Thromb Haemost; 1988 Jun; 59(3):349-52. PubMed ID: 2847347 [TBL] [Abstract][Full Text] [Related]
5. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia. McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730 [TBL] [Abstract][Full Text] [Related]
6. Antiserum against factor IX shortens the bovine thromboplastin coagulation time of human plasma. Orstavik KH; Laake K Thromb Res; 1978 Mar; 12(3):455-65. PubMed ID: 653636 [No Abstract] [Full Text] [Related]
8. Studies on the prolonged prothrombin time in haemophilia BM. Elödi S Thromb Diath Haemorrh; 1973 May; 29(2):247-52. PubMed ID: 4796945 [No Abstract] [Full Text] [Related]
9. [Blood coagulation disorders caused by abnormal blood coagulation factors]. Fiedler H Z Arztl Fortbild (Jena); 1972 Jul; 66(13):692-8. PubMed ID: 4636972 [No Abstract] [Full Text] [Related]
10. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Schimpf K; Schwarz P; Kunschak M Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845 [No Abstract] [Full Text] [Related]
11. [Hemophilia: pathophysiology, diagnosis and treatment (author's transl)]. Ito M Nihon Naika Gakkai Zasshi; 1976 Jun; 65(6):543-59. PubMed ID: 789795 [No Abstract] [Full Text] [Related]
12. Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor. Osterud B; Kasper CK; Lavine KK; Prodanos C; Rapaport SI Thromb Haemost; 1981 Feb; 45(1):55-9. PubMed ID: 7245126 [TBL] [Abstract][Full Text] [Related]
13. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management. Mahasandana C; Patharathienskul D; Suvatte V Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549 [TBL] [Abstract][Full Text] [Related]
14. Recent advances in the management of the child who has hemophilia. Dunn AL; Abshire TC Hematol Oncol Clin North Am; 2004 Dec; 18(6):1249-76, viii. PubMed ID: 15511615 [TBL] [Abstract][Full Text] [Related]
15. Management of the haemophiliac factor. Coutts AM Cent Afr J Med; 1997 Sep; 43(9):277-8. PubMed ID: 9509651 [No Abstract] [Full Text] [Related]
16. [Advances in the field of hemophilia therapy]. Loeliger EA; Veltkamp JJ Ned Tijdschr Geneeskd; 1968 Sep; 112(36):1593-5. PubMed ID: 5680135 [No Abstract] [Full Text] [Related]
17. Specific therapy in hemophilia. Hutaff LW N C Med J; 1973 Mar; 34(3):193-6. PubMed ID: 4510809 [No Abstract] [Full Text] [Related]
18. Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B. Thompson AR J Clin Invest; 1977 May; 59(5):900-10. PubMed ID: 856873 [TBL] [Abstract][Full Text] [Related]
19. An immunological method for detection of the carrier of hemophilia B. Matsuoka M; Ito M; Takahashi K; Sakuragawa N Thromb Haemost; 1976 Nov; 36(2):441-50. PubMed ID: 1036844 [TBL] [Abstract][Full Text] [Related]
20. From hemophilia B to hemophilia A via the fragile X locus: genes and recombination in the distal region of the human X chromosome long arm. Oberlé I; Mandel JL Horiz Biochem Biophys; 1986; 8():51-89. PubMed ID: 2875934 [No Abstract] [Full Text] [Related] [Next] [New Search]